CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine
- 1 February 2008
- Vol. 26 (9) , 1243-1252
- https://doi.org/10.1016/j.vaccine.2007.12.027
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Ten tandem repeats of β-hCG 109–118 enhance immunogenicity and anti-tumor effects of β-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65Biochemical and Biophysical Research Communications, 2006
- Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus☆Molecular Immunology, 2006
- Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult VolunteersJournal of Virology, 2006
- Prospects for Universal Influenza Virus VaccineEmerging Infectious Diseases, 2006
- Combinatorial Approach to Hepadnavirus-Like Particle Vaccine DesignJournal of Virology, 2005
- Roles of CD4+T-Cell-Independent and -Dependent Antibody Responses in the Control of Influenza Virus Infection: Evidence for Noncognate CD4+T-Cell Activities That Enhance the Therapeutic Activity of Antiviral AntibodiesJournal of Virology, 2005
- Vaccine development strategies for improving immunization: the role of modern immunologyNature Immunology, 2004
- A “universal” human influenza A vaccineVirus Research, 2004
- Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2Vaccine, 2003
- Cytotoxic T-Cell Immunity to InfluenzaNew England Journal of Medicine, 1983